Organogenesis Holdings Inc. has secured a $130 million private placement deal with Avista Healthcare Partners to bolster its strategic growth, repay debt, and repurchase shares. This investment, ...
Net proceeds to fund the Company’s strategic growth initiatives, enhance balance sheet flexibility, and finance privately negotiated stock repurchasesCANTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ...
Organogenesis (NASDAQ:ORGO – Get Free Report) will release its earnings data after the market closes on Tuesday, November ...
Organogenesis (ORGO) Holdings announced that it has entered into a subscription agreement with affiliates of Avista Healthcare Partners for the sale of its Series A convertible preferred stock in a ...
"They are expanding their production facility to produce a line of artificial skin,” said Jeff Miller, EVP of investments and ...
The Rhode Island Commerce Corporation is scheduled to meet on Thursday morning to consider millions of dollars in incentives ...
Medicare reimbursement issues expected for certain of Organogenesis' skin substitute projects disrupting revenues in 2025. Major catalyst is expected for ORGO with BLA filing in late 2025.
Organogenesis is a regenerative medicine company with an advanced wound care niche, and it's looking to take over a ...
Reports Q3 revenue $115.2M, consensus $108.83M.”Our third quarter results underscore the strength of our portfolio and brand equity as ...